Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis
Background: In recent years, the rise of antibody-drug conjugates (ADCs) has changed the treatment paradigm for patients with HER2-low advanced breast cancer (ABC). DESTINY-Breast04 (NCT03734029) has demonstrated the antitumor activity of trastuzumab deruxtecan (T-DXd). However, the balance between...
Sparad:
| Huvudskapare: | , , , , |
|---|---|
| Materialtyp: | Bok |
| Publicerad: |
Frontiers Media S.A.,
2022-10-01T00:00:00Z.
|
| Ämnen: | |
| Länkar: | Connect to this object online. |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signum: |
A1234.567 |
|---|---|
| Exemplar 1 | Tillgänglig |